158 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BMRN BioMarin Pharmaceutical Inc. $98.11 $17.42B N/A
Article Searches
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal http://www.zacks.com/stock/news/655819/4-solid-gene-therapy-buyout-bets-post-audentes-astellas-deal?cid=CS-ZC-FT-analyst_blog|industry_focus-655819 Dec 05, 2019 - Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
REGN or BMRN: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/645048/regn-or-bmrn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-645048 Nov 28, 2019 - REGN vs. BMRN: Which Stock Is the Better Value Option?
BMRN: Barclays ups to Overweight https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20191127082510 Nov 27, 2019 - Barclays issues rating change for BMRN
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal http://www.zacks.com/stock/news/638202/4-big-drug-stocks-ripe-for-takeover-after-nvs-mdco-deal?cid=CS-ZC-FT-analyst_blog|industry_focus-638202 Nov 26, 2019 - Here are four stocks that boast promising prospects and are most likely to be takeout targets.
BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A http://www.zacks.com/stock/news/632905/biomarin-files-maa-to-ema-for-gene-therapy-of-hemophilia-a?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-632905 Nov 22, 2019 - BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
REGN or BMRN: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/615903/regn-or-bmrn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-615903 Nov 12, 2019 - REGN vs. BMRN: Which Stock Is the Better Value Option?
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates http://www.zacks.com/stock/news/610537/sarepta-srpt-q3-loss-widens-y-y-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-610537 Nov 08, 2019 - Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
Can The Uptrend Continue for BioMarin Pharmaceutical? http://www.zacks.com/stock/news/592464/can-the-uptrend-continue-for-biomarin-pharmaceutical?cid=CS-ZC-FT-tale_of_the_tape|20_day_moving_average-592464 Oct 30, 2019 - As of late, it has definitely been a great time to be an investor BioMarin Pharmaceutical.
BioMarin (BMRN) Upgraded to Buy: What Does It Mean for the Stock? http://www.zacks.com/stock/news/590296/biomarin-bmrn-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-590296 Oct 29, 2019 - BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HZNP or BMRN: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/581983/hznp-or-bmrn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-581983 Oct 24, 2019 - HZNP vs. BMRN: Which Stock Is the Better Value Option?

Pages: 123456...16

Page 1>